Navigation Links
Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
Date:6/18/2010

SHENZHEN, China, June 18 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

    Financial Results for the Quarter Ended March 31, 2010

    -- Net revenue increased 25.6% to RMB 113.3 million ($16.6 million)
       (note 1), from RMB 90.2 million in the prior year period.
    -- Operating loss was RMB 9.7 million ($1.4 million), compared to an
       operating loss of RMB 10.3 million in the prior year period.
    -- Net loss attributable to the Company was RMB 13.4 million ($2.0
       million), which yielded net loss per ADS of RMB 0.52 ($0.08) and net
       loss per share(note 2) of RMB 0.13 ($0.02).
    -- Non-GAAP loss per share was RMB 0.04 ($0.01), compared to non-GAAP loss
       per share of RMB 0.01 in the first quarter of 2009.

Xiaochun Wang, Chief Executive Officer and Chairman of Tongjitang, stated, "Our first quarter performance reflects strong revenue improvement in our pharmaceutical business. During the first quarter, we expanded our sales networks into community hospitals to better align ourselves with the government's reform efforts, which focused on rural areas. Even though the pace of National Essential Drug List ("EDL") implementation by the local governments has been much slower than expected, we anticipate a notable increase in sales of EDL drugs beginning in the later part of this year."

Net revenue in the first quarter of 2010 increased 25.6% to RMB 113.3 million ($16.6 million) from RMB 90.2 million in the first quarter of 2009. Xianling Gubao ("XLGB") sales were RMB 54.5 million ($8.0 million) in the first quarter of 2010, compared to RMB 54.8 million in the first quarter of 2009. Net revenue from Moisturizing & Anti-itching Capsules and Zaoren Anshen Capsules reached RMB 14.7 million ($2.2 million) in the first quarter of 2010, compared to RMB 15.0 million in the first quarter of 2009. Net revenue from the Company's other products increased 116.2% to RMB 44.1 million ($6.4 million) from RMB 20.4 million in the first quarter of 2009. Revenue contribution from Anhui Jingfang Pharmaceutical Co., Ltd. ("Jingfang"), which was acquired at the end of the first quarter of 2009, was RMB 18.8 million ($2.8 million), compared to RMB14.0 million in the fourth quarter of 2009.

Gross profit increased 18.7% to RMB 62.3 million ($9.1 million) in the first quarter of 2010 from RMB 52.5 million in the first quarter of 2009. Gross margin was 55.0% in the first quarter of 2010, compared to 58.2% in the same period of 2009. Tongjitang's gross margin reflects higher revenue contribution from lower-margin products, as well as increased costs of raw materials, other than barrenwort, related to herbal medicines. Market price of barrenwort has remained relatively stable and we have maintained adequate inventory.

Operating loss in the first quarter of 2010 was RMB 9.7 million ($1.4 million), compared to an operating loss of RMB 10.3 million in the first quarter of 2009. Operating loss was mainly attributable to: 1) increased selling and marketing expenses, reflecting the Company's efforts to invest in its sales team's infrastructure and EDL sales network; and 2) expenses incurred in enhancing the branding and marketing effort of Guizhou Gui Liquor Co., Ltd., a company we restructured and renamed in connection with our acquisition of a state-owned distillery business in Guiyang at the beginning of the first quarter of 2010.

Net loss attributable to the Company was RMB 13.4 million ($2.0 million), which yielded net loss per ADS of RMB 0.52 ($0.08) and net loss per share(note 2) of RMB 0.13 ($0.02).

Non-GAAP adjusted EBITDA in the first quarter of 2010 was negative RMB 3.7 million ($0.5 million), compared to negative RMB 1.9 million in the first quarter of 2009. Non-GAAP adjusted EBITDA per share was negative RMB 0.04 ($0.01) in the first quarter of 2010, compared to negative RMB 0.01 in the first quarter of 2009. For the first quarter of 2010, the number of shares used in the computation of GAAP earnings per share and Non-GAAP adjusted EBITDA per share was 104.1 million, compared to 135.2 million in the prior year period. Please refer to the Company's GAAP to non-GAAP reconciliation table provided below for additional details.

Balance Sheet

As of March 31, 2010, the Company had cash and cash equivalents of RMB 208.1 million ($30.5 million). This compares to RMB 237.6 million as of December 31, 2009 and RMB 488.4 million as of March 31, 2009.

Business Updates

On April 8, 2010, the Company announced that it received a letter proposing to acquire all of the outstanding ordinary shares of the Company, including ordinary shares outstanding in the form of American Depositary Shares ("ADSs"), in a transaction under Cayman Islands law that would, if the proposal is accepted, result in the Company becoming a privately-held company. The proposal was from Hanmax Investment Limited, a company controlled by Mr. Xiaochun Wang, chairman of the Company's board of directors (the "Board") and chief executive officer of the Company, and Fosun Industrial Co., Limited, a company incorporated in Hong Kong. On April 12, 2010, the Company announced that it established a special committee of the Board ("Independent Committee"), comprised of the Company's three independent directors, to evaluate the proposal. On June 1, 2010, the Independent Committee announced that Morgan Stanley Asia Limited has been appointed as its independent financial advisor. In addition, the Independent Committee retained Sheppard, Mullin, Richter & Hampton LLP to serve as its United States law counsel and Thorp Alberga to serve as its Cayman Islands law counsel.

About Non-GAAP Financial Measures

To supplement the Company's unaudited condensed consolidated financial information presented in accordance with the United States Generally Accepted Accounting Principles ("GAAP"), the Company also provides non-GAAP financial measures, non-GAAP adjusted EBITDA and non-GAAP adjusted EBITDA per share, all of which exclude depreciation and amortization, interest (income) expense, provision for income taxes and share-based compensation expenses recorded under FASB Accounting Standards Codification ("ASC") Subtopic 718 - 10 Compensation - Stock Compensation: Overall (Pre-codification: SFAS No. 123(R), Share-Based Payment.) The Company's management believes the non-GAAP financial measures facilitate better understanding of operating results from quarter to quarter and allows the management team to better plan and forecast future periods, as the non-GAAP financial measures provide additional information to the investors. The non-GAAP information is not in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for the GAAP results. A limitation of using these non-GAAP financial measures is that these non-GAAP measures exclude share-based compensation expenses that have been and will continue to be significant recurring expenses in our business for the foreseeable future. Reconciliations of the Company's non-GAAP financial data to the most comparable GAAP data are included at the end of this press release.

Conference Call

Tongjitang's management team will hold a conference call on June 21 at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:

    United States toll free:   1-888-287-5516
    Hong Kong toll free:       800-968-103
    Northern China toll free:  10-800-712-0046
    Southern China toll free:  10-800-120-0046
    International:             1-719-325-2101

    Listeners may access the replay through June 28, 2010, by dialing the
following numbers:

    United States toll free:   1-888-203-1112
    International:             1-719-457-0820
    Password:                  4613425

An audio webcast of the call will also be available through the Company's website at http://www.tongjitang.com .

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 36 western medicines. Please visit http://www.tongjitang.com for more information.

Safe Harbor Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from those described in the forward-looking statements in this press release. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's heavy dependence on the success of Xianling Gubao; the Company's ability to market Xianling Gubao to hospitals and to retail pharmacies; the retail prices of its principal products' being subject to price control by the government authorities in China; the inclusion of the Company's products in national and provincial medical catalogs of the National Medical Insurance Program in China; the Company's ability to obtain approval from the State Food and Drug Administration in China to convert a provisional national production standard of the Company's principal products to a national final production standard; the Company's ability to continue having the exclusive production rights for its products; the Company's ability to further improve its barrenwort extraction efficiency; the presence of certain side effects in the Company's current products and the Company's ability to identify side effects associated with its current or future products prior to their marketing and sale; the Company's ability to obtain manufacturing or marketing approval for its future products; the Company's dependence on a limited number of distributors for a significant portion of its net revenues; the Company's exposure to the risk of product liability claims and its limited insurance coverage; the Company's ability to manage the expansion of its operations and its future research and development projects successfully; the Company's ability to protect its intellectual property rights and defend infringement or misappropriation claims by third parties; intense competition in the pharmaceutical market in China; the supply of quality medicinal raw materials; uncertainties with respect to the legal system in China, including uncertainty with respect to potential regulatory changes in China's healthcare industry; if disruptions in the financial markets and other macro-economic challenges currently affecting the economy of the United States and other parts of the world continue or even worsen, it may adversely impact the economy and consumer confidence in China; the Company's ability to expand its business through organic growth and strategic acquisitions and investments; and the Company's ability to integrate its acquisitions, including the recently-acquired state-owned distillery business in Guiyang . Further information regarding these and other risks is and will be included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of the date of this press release, and the Company undertakes no duty to update such information, except as required under applicable law.

(Note 1) This announcement contains translations of certain Renminbi amounts into US dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to US dollars as of and for the quarter ended March 31, 2010 were made at the noon buying rate on March 31, 2010 in the City of New York for cable transfers in Renminbi per US dollar as certified for customs purposes by the Federal Reserves Bank of New York, which was RMB6.8258 to USD1.00. Tongjitang makes no representation that the Renminbi or US dollar amounts referred to in this release could have been or could be converted into US dollars or Renminbi, as the case may be, at any particular rate or at all.

(Note 2) All references to 'shares' are to our ordinary shares. Each of our American Depositary Shares, which are traded on the New York Stock Exchange, represents four ordinary shares.

    CONTACT:

    ICR, Inc.
     Ashley M. Ammon or Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)




                       Tongjitang Chinese Medicines Company
                 Condensed Consolidated Statements of Operations
                 (In thousands, except share and per share data)

                                           First Quarter Ended March 31
                                          2009           2010          2010
                                           RMB            RMB           US$
                                                                       (Note)
    Net revenues                           90,179        113,283       16,596
    Cost of revenues                       37,665         50,941        7,463
    Gross profit                           52,514         62,342        9,133
    Advertising expenses                  (12,883)        (3,481)        (510)
    Other selling and marketing
     expenses                             (30,566)       (49,122)      (7,197)
    General and administrative
     expenses                             (17,010)       (18,279)      (2,678)
    Research and development expenses      (2,813)        (2,060)        (302)
    Government grant (related to
     research and development)                 10             --           --
    Other operating income                    496            916          134
    Income (loss) from operations         (10,252)        (9,684)      (1,420)
    Other income (expenses):
        Interest income                     1,437            458           67
        Interest expense                   (2,132)        (2,490)        (365)
        Government grants                   1,365          1,192          175
        Investment (loss) / gain              (16)            51            7
        Other income / (expenses),
         net                                  303           (337)         (49)
    Loss before income taxes and non-
     controlling interests                 (9,295)       (10,810)      (1,585)
    Provision for income taxes             (2,042)        (2,739)        (401)
    Net loss                              (11,337)       (13,549)      (1,986)
    Less: Net income (loss)
     attributable to the non-
     controlling interests                    (25)           140           21
    Net loss attributable to the
     Company                              (11,362)       (13,409)      (1,965)

    Earnings per share
        Ordinary shares
        -Basic                              (0.08)         (0.13)       (0.02)
        -Diluted                            (0.08)         (0.13)       (0.02)

    Shares used in computation of
     earnings per share
        Ordinary shares
        -Basic                        135,209,722    104,066,526  104,066,526
        -Diluted                      135,209,722    104,066,526  104,066,526

    (Note)

    The condensed consolidated financial statements of Tongjitang Chinese
    Medicines Company are stated in Renminbi ("RMB"). The translation of RMB
    amounts as of and for the period ended March 31, 2010 into United States
    dollar ("US$") is included solely for the convenience of readers and has
    been made at the rate of RMB6.8258 to US$1.00, which is based on the noon
    buying rate in The City of New York for cable transfers of Renminbi as
    certified for customs purposes by the Federal Reserve Bank of New York at
    March 31, 2010. Such translations should not be construed as
    representations that RMB amounts could be converted into US$ at that rate
    or any other rate.


                      Tongjitang Chinese Medicines Company
                      Condensed Consolidated Balance Sheets
                        (In thousands, except share data)

                                           Dec. 31        Mar. 31    Mar. 31
                                             2009          2010       2010
                                             RMB           RMB        US$
                                                                    (Note 1)
    ASSETS
    Current assets:
      Cash and cash equivalents              237,578       208,145    30,494
      Short-term bank deposit                 50,000        52,500     7,691
      Notes receivable                        70,248        60,728     8,897
      Accounts receivable, net of
       allowance for doubtful accounts       232,038       240,253    35,198
      Inventories                            139,100       167,348    24,517
      Trading securities                       1,447         1,512       222
      Prepaid advertising expenses             1,204         1,147       168
      Receivable on sales of property,
       plant and equipment                     9,320         9,320     1,365
      Other prepaid expenses and current
       assets, net of allowance
       for doubtful accounts                  16,139        26,816     3,928
      Deferred tax assets                      7,565         6,508       953
               Total current assets          764,639       774,277   113,433
    Investment property (Note 2)                  --        78,486    11,498
    Property, plant and equipment, net
     (Note 2)                                172,097       173,898    25,477
    Land use rights, net                      42,515        43,181     6,326
    Deposit for acquisition of a
     subsidiary                              120,599            --        --
    Deposits for acquisition of property,
     plant and equipment, and
     intangible assets                       162,440       172,331    25,247
    Deferred tax assets                        2,809         2,652       389
    Long-term other assets                     1,000         1,752       257
    Acquired intangible assets, net (Note 2)  27,592        27,711     4,060
    Goodwill (Note 2)                          2,345        81,868    11,994
    Receivable on sales of property,
     plant and equipment                       9,170         6,840     1,002
              Total assets                 1,305,206     1,362,996   199,683

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current liabilities:
      Short-term borrowings                  101,100       112,522    16,485
      Accounts payable                        38,288        41,302     6,051
      Accrued expenses and other current
       liabilities                           156,247       185,973    27,246
      Income taxes payable                     3,089         2,589       379
      Unrecognized tax benefit                   937           962       141
      Amounts due to related parties           6,086        13,948     2,043
               Total current liabilities     305,747       357,296    52,345
    Long-term bank loans                      50,000        50,000     7,325
    Deferred tax liabilities                  11,868        29,236     4,283
               Total liabilities             367,615       436,532    63,953

    Total shareholders' equity
     attributable to the Company             937,591       924,759   135,480

    Non-controlling interest                      --         1,705       250

    Total equity                             937,591       926,464   135,730

               Total liabilities and
                equity                     1,305,206     1,362,996   199,683

    (Note 1)
    The condensed consolidated financial statements of Tongjitang Chinese
    Medicines Company are stated in Renminbi ("RMB"). The translation of RMB
    amounts as of and for the period ended March 31, 2010 into United States
    dollar ("US$") is included solely for the convenience of readers and has
    been made at the rate of RMB6.8258 to US$1.00, which is based on the noon
    buying rate in The City of New York for cable transfers of Renminbi as
    certified for customs purposes by the Federal Reserve Bank of New York at
    March 31, 2010. Such translations should not be construed as
    representations that RMB amounts could be converted into US$ at that rate
    or any other rate.

    (Note 2)
    We are in the process of performing valuations of certain identifiable
    investment property, property, plant and equipment, land use rights and
    intangible assets for the acquisitions we completed in the first quarter
    of 2010 and hence the net book value for investment property, property,
    plant and equipment, land use rights and intangible assets and goodwill
    is preliminary and subject to revision once we complete the valuation
    exercise.



                       Tongjitang Chinese Medicines Company
                        Reconciliation of GAAP to Non-GAAP
                 (In thousands, except share and per share data)

                                             First Quarter Ended March 31
                                            2009         2010         2010
                                             RMB          RMB          US$
                                                                      (Note 1)
    GAAP net income                         (11,362)     (13,409)      (1,965)
    Share-based compensation expenses
     (Note 2)                                 2,035          133           19
    Depreciation and amortisation             4,669        4,797          703
    Interest (income) expense, net              695        2,032          298
    Provision for income taxes                2,042        2,739          401

    Non-GAAP adjusted EBITDA                 (1,921)      (3,708)        (544)

    GAAP earnings per share
        Ordinary shares
        -Basic                                (0.08)       (0.13)       (0.02)
        -Diluted                              (0.08)       (0.13)       (0.02)

    Non-GAAP adjusted EBITDA per share
        Ordinary shares
        -Basic                                (0.01)       (0.04)       (0.01)
        -Diluted                              (0.01)       (0.04)       (0.01)

    Shares used in computation of GAAP
     earnings per share / Non-GAAP
     adjusted EBITDA per share
        Ordinary shares
        -Basic                          135,209,722  104,066,526  104,066,526
        -Diluted                        135,209,722  104,066,526  104,066,526

    (Note 1)

    The condensed consolidated financial statements and the related amounts of
    Tongjitang Chinese Medicines Company are stated in Renminbi ("RMB"). The
    translation of RMB amounts as of and for the period ended March 31, 2010
    into United States dollar ("US$") is included solely for the convenience
    of readers and has been made at the rate of RMB6.8258 to US$1.00, which is
    based on the noon buying rate in The City of New York for cable transfers
    of Renminbi as certified for customs purposes by the Federal Reserve Bank
    of New York at March 31, 2010. Such translations should not be construed
    as representations that RMB amounts could be converted into US$ at that
    rate or any other rate.


    (Note 2)
    Share-based compensation expenses recorded in accordance to ASC subtopic
    718-10 ("ASC 718-10"), Compensation - Stock Compensation: Overall
    (Pre-codification: SFAS No.123(R), Share-Based Payment) are as follows:


                                            First Quarter Ended March 31
                                              2009         2010         2010
                                               RMB          RMB          US$
                                                                      (Note 1)
    General and administrative expenses       2,035          133           19


'/>"/>
SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
2. Biosites Triage Products Seized by Beijing Customs; Chinese Market Facing Shortage
3. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
4. Chinese Distribution Contract Extended for an Additional 4 Years
5. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
7. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
8. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
9. GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms
10. Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016 PLAD, Inc. (OTC Pink: PLAD) is ... sales exceeding company targets, are adding key personnel to ... from the United States Patent and Trademark Office for ... Executive Officer of PLAD, Inc.  In January, PLAD established ... with two new customers, Cumberland Goodwill EMS ...
(Date:2/11/2016)... February 11, 2016 F ast ... answers at the ... provider of scientific, technical and medical information products and services, has launched ... peer reviewed clinical information via a mobile device. Elsevier designed the mobile ... Nursing. The new app is available in Android and ...
(Date:2/11/2016)... Ohio , Feb. 11, 2016  Community pharmacists ... increasing efficiency for the pharmacy through a custom-built medication ... Schieber , pharmacist and owner at Schieber Family ... "We can get a lot of patients enrolled in ... for everybody. It,s a win for the patient, and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Western University ... health services to the developmentally disabled in the Coachella Valley. , The two ... new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, California. The ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
Breaking Medicine News(10 mins):